Association of cerebrospinal fluid Aβ42 with A2M gene in cognitively normal subjects by Millard, Steven P. et al.
Association of cerebrospinal fluid Aβ42 with A2M gene in
cognitively normal subjects
Steven P. Millarda,*, Franziska Lutzb,c, Ge Lid, Douglas R. Galaskoe, Martin R. Farlowf,
Joseph F. Quinng, Jeffrey A. Kayeg, James B. Leverenzd,h, Debby Tsuangb,d, Chang-En
Yub,c, Elaine R. Peskinda,d, and Lynn M. Bekrisb,c
aNorthwest Network VISN-20 Mental Illness Research, Education, and Clinical Center, Seattle,
WA, 98108, USA
bGeriatric Research, Education, and Clinical Center, Seattle, WA, 98108, USA
cDepartment of Medicine, University of Washington, Seattle, WA, 98195, USA
dDepartment of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA,
98195, USA
eDepartment of Neurosciences, University of California at San Diego, San Diego, CA, 92093,
USA, and VA Medical Center San Diego, San Diego, CA, 92161, USA
fDepartment of Neurology, Indiana University School of Medicine, Indianapolis, IN, 46202, USA
gDepartment of Neurology, Oregon Health and Science University, Portland, OR, 97239, USA,
and Portland VA Medical Center, Portland, OR, 97239, USA
hDepartment of Neurology, University of Washington, Seattle, WA, 98195, USA, and Northwest
Network VISN-20 Parkinson’s Disease Research, Education, and Clinical Center, VA Puget
Sound Health Care System, Seattle, WA, 98108, USA
Abstract
Low cerebrospinal fluid (CSF) Aβ42 levels correlate with increased brain Aβ deposition in
Alzheimer’s disease (AD), which suggests a disruption in the degradation and clearance of Aβ
from the brain. In addition, APOE ε4 carriers have lower CSF Aβ42 levels than non-carriers. The
hypothesis of this investigation was that CSF Aβ42 levels correlate with regulatory region
variation in genes that are biologically associated with degradation or clearance of Aβ from the
brain. CSF Aβ42 levels were tested for associations with Aβ degradation and clearance genes and
APOE ε4. Twenty-four SNPs located within the 5′ and 3′ regions of 12 genes were analyzed. The
study sample consisted of 99 AD patients and 168 cognitively normal control subjects. CSF Aβ42
levels were associated with APOE ε4 status in controls but not in AD patients; A2M regulatory
region SNPs were also associated with CSF Aβ42 levels in controls, but not in AD patients, even
after adjusting for APOE ε4. These results suggest that genetic variation within the A2M gene
influences CSF Aβ42 levels.
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1 Introduction
Amyloid precursor protein (APP) is an integral membrane protein that is expressed in many
cell types, including neurons (Brunholz, et al., 2012, Chasseigneaux and Allinquant, 2012).
APP has been implicated in synapse formation and neuronal plasticity (Hoe, et al., 2012,
Marcello, et al., 2012), but it is best known as the protein whose cleavage generates amyloid
beta (Aβ), a peptide that is the primary component of the amyloid plaques found in
Alzheimer’s disease (AD) (Hyman, 2011).
Many proteins are involved in the posttranslational cleavage of APP into Aβ, but there are
two main pathways through which APP appears to undergo cleavage. In a pathway that
negates the production of Aβ, an APPα fragment is produced through cleavage by the
enzyme α-secretase. A number of proteins have been implicated as having α-secretase
activity, including ADAM10 (Deuss, et al., 2008, Postina, 2008). In an alternative cleavage
pathway, a soluble APPβ fragment and a C terminal fragment (βCTF) are produced through
APP cleavage by β-secretase, perhaps by two enzymes, BACE1 and BACE2, that are known
to have β-secretase activity (Ewers, et al., 2008, Stockley and O’Neill, 2007, Sun, et al.,
2005, Wu, et al., 2008, Zetterberg, et al., 2008). The βCTF produced by this β-secretase
activity is bound to the membrane and can subsequently undergo γ-secretase cleavage to
produce an Aβ peptide ranging in size from 35–42 amino acids. Several protein subunits
form the γ-secretase protein complex, including presenilin (either presenilin 1 or presenilin
2), nicastrin, APH1, and PEN2 (Baulac, et al., 2003, Francis, et al., 2002, Kimberly, et al.,
2003).
Multiple APP cleavage products, including Aβ, are normally present in the brain and
cerebrospinal fluid (CSF) (Seubert, et al., 1992), and the levels of these cleavage products
may be associated with cognitive decline. For example, low CSF Aβ42 levels are associated
with age and the apolipoprotein E (APOE) ε4 genotype in cognitively normal adults
(Peskind, et al., 2006), and CSF Aβ42 levels are significantly lower in patients with AD and
mild cognitive impairment compared to cognitively normal controls (Galasko, et al., 1998,
Motter, et al., 1995, Sunderland, et al., 2003). In addition, low CSF Aβ42 levels are
associated with both AD and Aβ deposition in the brain (Fagan, et al., 2006, Tapiola, et al.,
2009, Visser, et al., 2009).
Evidence suggests that the steady-state levels of CSF Aβ are maintained not only by its
production but also by its degradation and clearance (Sagare, et al., 2012). Modulated
production and clearance of the Aβ peptide in the brain is implicated in the complex
pathological cascade of AD, which may be caused by overproduction of the Aβ peptide or
by impaired clearance of Aβ from the brain. Clearance decreases with increased aggregation,
decreased degradation, disturbed blood-brain barrier transport, or inefficient peripheral
removal of the peptide (Liu, et al., 2012, Miners, et al., 2011, Sagare, et al., 2012). Previous
studies have shown that ApoE interacts with and promotes the clearance of Aβ from the
interstitial fluid of the brain (Castellano, et al., 2011). Many other proteins have been
associated with Aβ degradation and clearance in AD, including neprilysin, endothelin-
converting enzyme, angiotensin I converting enzyme, insulin-degrading enzyme,
plasminogen, matrix metallopeptidase 9, receptor for advanced glycation end products, low-
density lipoprotein receptor-related protein 1, low-density lipoprotein receptor-related
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protein 8, ATP-binding cassette, sub-family B (P-glycoprotein), clusterin (apolipoprotein J),
and α2-macroglobulin (Liu, et al., 2012, Miners, et al., 2011, Sagare, et al., 2012).
Given that multiple proteins have been associated with the degradation and clearance of Aβ,
and that lower CSF Aβ42 levels are associated with AD, older age, and the APOE ε4 allele,
we hypothesized that SNPs within the noncoding regions of genes that encode proteins
biologically implicated in the degradation and clearance of Aβ may correlate with CSF Aβ42
levels. We therefore analyzed the relationship between CSF Aβ42 levels and 24 SNPs
located within the 5′ and 3′ regions of 12 Aβ degradation and clearance genes, as well as
APOE SNPs that designate the APOE ε4 allele, while taking into account age, gender, race,
and APOE ε4 status.
2 Methods
2.1 Participants
Following informed consent, 168 healthy, cognitively normal, older control subjects (age >
51) and 99 AD patients (Table 1) underwent extensive evaluation that consisted of medical
history, family history, physical and neurologic examination, laboratory tests, and
neuropsychological assessment; information was obtained from participants and from
informants for all AD patients. All procedures were approved by the institutional review
boards of the participating institutions.
All control subjects were found to have normal cognition after undergoing a thorough
clinical and neuropsychological assessment including Logical memory (immediate and
delayed), Category fluency for animals and Letter S, and Trail Making tests A and B. All
controls had Mini-Mental State Exam (MMSE) scores > 26 and Clinical Dementia Rating
(CDR) scale scores of 0 (Peskind, et al., 2006).
All AD patients were participants in research clinical cores at their respective institutions.
Clinical diagnoses of AD were made according to well-established consensus criteria
(McKhann, et al., 1984, Petersen, et al., 1999). No AD patients had a known AD-causing
mutation or a family history of AD that would suggest autosomal-dominant AD.
2.2 Cerebrospinal fluid (CSF)
All CSF samples were collected in the morning after participants fasted overnight. CSF
samples were collected using the Sprotte 24-g traumatic spinal needle while participants
were in either a lateral decubitus or sitting position (Peskind, et al., 2006, Peskind, et al.,
2005). The samples were aliquoted at the bedside, frozen immediately on dry ice, and then
stored at −80°C until they were assayed. Results reported here are from assays run from
comparable lumbar puncture fractions to limit variability from rostrocaudal concentration
gradients. Aβ42 was measured using a sensitive multiplex xMAP Luminex platform
(Luminex Corp, Austin, TX) with Innogenetics (INNO-BIA AlzBio3; Ghent, Belgium; for
research use–only reagents) as previously described (Olsson, et al., 2005, Shaw, et al.,
2009). The intra-assay coefficient of variation was < 10% for all assays.
2.3 Genes and SNP selection
Twelve genes were chosen for their biologically characterized role in APP degradation and
clearance. SNPs were chosen within these genes according to the following criteria: (1) A
chosen SNP was located within a known or putative regulatory region of the gene, and when
necessary, tagging SNPs were chosen to capture putative regulatory regions; (2) a chosen
SNP had a minor allele frequency (MAF) of ≥ 0.1 in the HapMap Caucasian (CEU)
population and a minor genotype frequency in our study sample of ≥ 0.01; and (3) a SNP
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genotyping assay was commercially available for a chosen SNP. Based on these criteria, 24
SNPs were selected (Table 2). An additional SNP (rs429358) was also genotyped to
determine APOE ε4 status.
2.4 SNP genotyping
Genomic DNA was genotyped using TaqMan allelic discrimination detection on 384 well
plates as described previously (Bekris, et al., 2008). For each reaction, SNP TaqMan Assay
(Applied Biosystems), TaqMan Universal PCR Master Mix (Applied Biosystems), and
DNA were pipetted into each well. PCR was carried out using a 9700 Gene Amp PCR
System (Applied Biosystems). Plates were then subjected to an end-point read on a 7900
Real-Time PCR System (Applied Biosystems). The results were first evaluated by cluster
variations; the allele calls were then assigned automatically before being integrated into the
genotype database.
2.5 Statistical analysis
SNP genotype frequencies (FF vs. EE vs. EF, where F denotes the major allele and E
denotes the minor allele) were tested for Hardy-Weinberg equilibrium and also compared
between groups (AD patients vs. control subjects) using the chi-squared test. To adjust for
age, gender, race, and APOE ε4 status, we performed logistic regression using these
covariates and the particular SNPs as predictor variables and the disease status as the
response variable. We also compared the frequency of collapsed genotype groups (absence
or presence of the minor allele; i.e., FF vs. combined EE and EF) between AD patients and
control subjects after adjusting for covariates. All subsequent analyses involving SNPs were
based on the collapsed genotype group.
CSF Aβ42 levels were initially compared between AD patients and control subjects using the
t-test. We then used a linear regression model to examine the relationship between APOE ε4
status and CSF Aβ42 levels while taking into account gender, age, race, and disease status.
This regression model included CSF Aβ42 level as the dependent variable; gender, age, race,
APOE ε4 status, and disease status as the predictor variables; and a disease status–by–APOE
ε4-status interaction term to allow for the effect of APOE ε4 status to potentially vary
between disease groups. Next, we used regression models to examine the relationship
between the SNPs and CSF Aβ42 levels. Each initial model (one for each SNP) included the
CSF Aβ42 level as the dependent variable and the same predictor variables as in the
previously described APOE ε4 model, along with the SNP and a disease status–by–SNP
interaction term to allow the effect of SNP to potentially vary between disease groups. In
cases where a significant SNP effect was found, we then investigated the effect of that SNP
separately within each disease status group, allowing for a SNP–by–APOE ε4-status
interaction term. Diagnostic plots of model residuals were inspected to assess any major
departures from normality or homoscedasticity.
As a sensitivity analysis, we constructed a random forest model (Breiman, 2001, Liaw,
2002) using CSF Aβ42 level as the dependent variable and disease status, gender, age, race,
APOE ε4 status, and all 24 SNPs as the predictor variables. The random forest algorithm
uses multiple tree-based models to predict Aβ42 levels, has built-in cross validation, and
inherently adjusts for interactions between predictor variables. The importance of a predictor
is quantified by the average increase in mean squared error across all trees that occurs when
the values of the predictor are randomly permuted for the out-of-bag (OOB) cases (i.e., the
set of observations that are not used for building the current tree). Following the
recommendation of Nicodemus et al. (Nicodemus, et al., 2010), we used unscaled measures
of importance in these analyses.
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Statistical analyses were performed in SPSS (version 14) and R (version 2.12.2; R
Development Core Team, 2009; http://www.R-project.org.). When correcting for multiple
comparisons, the Holm method was used (Holm, 1979).
3 Results
3.1 SNP genotype frequency
Twenty-four SNPs from 12 APP degradation- and clearance-related genes were genotyped
(Table 2). All 24 SNPs passed the test for Hardy-Weinberg equilibrium (i.e., p > 0.05 for all
tests). A comparison of genotype frequency between AD patients and control subjects
indicated that only the frequency of NEP rs12765 was significantly different between
disease groups, and this difference only occurred when the genotypes were collapsed into
two groups (i.e., major genotype FF vs. combined minor genotypes EE and EF), both before
and after adjusting for age, gender, race, and APOE ε4 status (unadjusted p = 0.020, adjusted
p = 0.038). However, after correcting for multiple comparisons, the significance of this
frequency difference disappeared.
3.2 CSF Aβ42 levels by disease group and APOE ε4 status
Figure 1 shows CSF Aβ42 levels for cognitively normal control subjects and AD patients,
including 95% confidence intervals for the means. We found that CSF Aβ42 levels were
significantly lower in AD patients (mean: 106 pg/ml, standard deviation (SD): 28 pg/ml)
than in controls (mean: 152 pg/ml, SD: 37 pg/ml; 46 pg/ml reduction, p < 0.001, effect size:
1.4, 95% confidence interval (CI) for reduction: 37, 54pg/ml). Figure 2 shows CSF Aβ42
levels by disease group and APOE ε4 status and includes unadjusted 95% confidence
intervals for the means. After controlling for gender, age, and race, there was a significant
disease group–by–APOE ε4-status interaction (p = 0.002). Control subject Aβ42 levels were
significantly lower for APOE ε4 carriers than non-carriers (31 pg/ml reduction, p < 0.001,
effect size: 1, 95% CI for reduction: 21, 41 pg/ml), whereas among AD patients there was no
significant difference in Aβ42 levels between APOE ε4 carriers and non-carriers (p = 0.46).
3.3 SNP genotype effect on CSF Aβ42 levels
Each SNP was tested individually for its effect on CSF Aβ42 levels in AD patients and
controls. Figure 3 shows the effect of SNP on Aβ42 levels for each of the 24 APP
degradation- and clearance-related SNPs based on the linear regression model described in
the Methods section. For each disease group (i.e., control subjects or AD patients), the figure
shows either an increase or decrease in Aβ42 level for the minor SNP group (EE, EF)
compared to the major SNP group (FF), including 95% confidence intervals unadjusted for
multiple comparisons. For example, Aβ42 levels were higher for minor allele carriers of the
A2M rs226379 SNP within the control group.
Within the control group, CSF Aβ42 levels were significantly higher for A2M rs1805667
minor allele carriers compared to major genotype carriers—and this significance remained
after performing a Holm correction for multiple comparisons (p = 0.002, Holm corrected p =
0.04) (Figure 3). CSF Aβ42 levels were also significantly higher for minor allele carriers
compared to major genotype carriers for the A2M rs226376 SNP, and this finding almost
achieved significance after correcting for multiple comparisons (p = 0.003, Holm corrected
p = 0.06). None of the other SNPs reached significance after correction for multiple
comparisons. For example, within the AD group, CSF Aβ42 levels were significantly higher
for minor allele carriers compared to major genotype carriers for the LRP1 rs7956957 SNP,
but this finding did not remain significant after correcting for multiple comparisons (p =
0.03, Holm corrected p = 0.63).
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3.4 Effect of APOE ε4, A2M rs226376, and rs1805667 genotype on CSF Aβ42 levels
The A2M gene was the only gene in this analysis that remained significant after performing
a Holm correction for multiple comparisons (Figure 3). The nature of this difference is
summarized in Figure 4 for both of the two relevant A2M SNPs: rs226376 and rs1805667.
The effects of these SNPs were analyzed separately for control subjects and AD patients,
and these analyses included gender, race, age, and APOE ε4 status as covariates, as well as a
SNP-by–APOE ε4-status interaction term. The effects of SNP and APOE ε4 were additive,
that is, neither of the SNPs displayed a significant SNP-by–APOE ε4 status interaction
effect, either within controls (p = 0.78 for rs226379, p = 0.46 for rs1805667) or within AD
patients (p = 0.36 for rs226379, p = 0.11 for rs1805667). Within control subjects, there was
a significant difference between minor allele carriers and major genotype carriers for both
SNPs, with the major genotype carriers showing decreased levels of Aβ42 (15 pg/ml
reduction, p = 0.017, effect size of 0.48, 95% CI for reduction: 3, 27 pg/ml for rs226379; 14
pg/ml reduction, p = 0.026, effect size of 0.45, 95% CI for reduction: 2, 26 pg/ml for
rs1805667). Just as with APOE ε4 (Figure 2), within AD patients there was no significant
difference in Aβ42 levels between allele carrier groups for either SNP (p = 0.78 for
rs226379; p = 0.49 for rs805667).
3.5 Random forest results
A random forest model with CSF Aβ42 level as the dependent variable and disease status,
gender, age, race, APOE ε4 status, and all 24 SNPs as the predictor variables explained 40%
of the variance in Aβ42 levels (Figure 5). The five most important variables, based on
unscaled importance, were disease status (diagnosis), APOE ε4 status, age, and the two A2M
SNPs: rs226376 and rs1805667.
4 Discussion
The aim of this investigation was to determine whether CSF Aβ42 levels correlate with
genetic variation in the regulatory regions of genes that are biologically associated with the
degradation and clearance of Aβ in the brain. We analyzed twelve of these genes for
correlations between the SNPs in their regulatory regions and CSF Aβ42 levels, and we
found that two SNPs in the A2M gene were significantly correlated with CSF Aβ42 levels.
Moreover, the 3′ region A2M SNP (rs1805667) remained significant after correction for
multiple comparisons (Figure 2). These results are supported by a random forest analysis
where the A2M SNPs were identified as the two most important variables for predicting CSF
Aβ42 levels after disease status, APOE ε4 status, and age (Figure 5).
In addition, we found that CSF Aβ42 levels in cognitively normal subjects were significantly
lower in APOE ε4 carriers than in non-carriers, whereas in AD patients the presence or lack
of an ε4 allele showed no relationship to CSF Aβ42 levels (Figure 2). These results are
consistent with previous reports in cognitively normal controls of lower Aβ levels in APOE
ε4 carriers than in ε4 non-carriers (Lim, et al., 2012, Peskind, et al., 2006). Given that
among controls CSF Aβ42 levels were lower in APOE ε4 carriers than in non-carriers, we
further hypothesized that the effect of APOE ε4 on CSF Aβ42 levels would be enhanced in
the presence of certain A2M genotypes. Indeed, cognitively normal controls who carried
A2M rare alleles (EF, EE) but not APOE ε4 had significantly higher CSF Aβ42 levels than
A2M common genotype (FF) carriers who also carried APOE ε4 (Figure 4). Given that low
CSF Aβ42 levels are associated with both AD and Aβ deposition in the brain (Fagan, et al.,
2006, Tapiola, et al., 2009, Visser, et al., 2009), these results suggest that A2M rare allele
carriers that are APOE ε4 non-carriers have the greatest level of protection against Aβ
deposition, whereas APOE ε4 carriers with the A2M common genotype are the most
susceptible to Aβ deposition.
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Interestingly, in AD patients, we found no relationship between CSF Aβ42 levels and APOE
genotype (Figure 2), nor between CSF Aβ42 levels and A2M genotype (Figure 4). This
suggests that although genotype may influence CSF Aβ42 levels in cognitively normal
controls, genotype does not appear to play a role once subjects have progressed to AD.
Furthermore, it is possible that other distant uncharacterized regulatory regions were not
detected using the regulatory region tagging SNPs chosen for this study, and this may
contribute to the lack of a CSF Aβ42 association with other Aβ clearance or degradation
genes in either AD or controls. Although an advantage of this investigation, in contrast to
genome-wide association studies, is that our hypothesis tested a specific biological pathway,
a limitation to this approach is that only a few SNPs were used to capture putative regulatory
genetic variation within and surrounding the genes of interest. In addition, a positive SNP
may represent a surrogate marker for a true functional SNP that was not analyzed in this
study. Additional functional studies are needed to fine-map the specific contribution of the
genetic variation within and surrounding the A2M gene to both protein activity and gene-
expression levels.
The A2M gene encodes alpha-2-macroglobulin (alpha2M), a protein which has many
diversified and complex functions, including the inhibition of a broad spectrum of proteases
without the direct blockage of the protease active site (Rehman, et al., 2013). When
activated by proteases, alpha2M functions as an extracellular chaperone that inhibits
amorphous and fibrillar protein aggregation (Wyatt, et al., 2013). It is also implicated in the
clearance of the extracellular Aβ constituent of amyloid plaques, where it acts as an
extracellular chaperone that helps control amyloid formation and toxicity in vivo (Wilson, et
al., 2008; Yerbury, et al., 2009, Yerbury and Wilson, 2010). A recent report on microglial
Aβ binding has shown that alpha2M facilitates the clearance of Aβ in AD, whereas in AD
with cerebral amyloid angiopathy, CD11b leads to Aβ accumulation (Zabel, et al., 2013).
An increase in alpha2M levels occurs in blood-brain barrier disruption and during
inflammation (Cucullo, et al., 2003). In addition, dimeric and tetrameric alpha2M play a role
in controlling amyloid fibril formation (Ozawa, et al., 2011), which suggests that the level of
alpha2M expression is critical in amyloid deposition. An increase in serum or plasma
alpha2M levels has also been reported in AD (Hye, et al., 2006, Zhang, et al., 2004).
However, other studies have found no difference between AD patients and cognitively
normal controls in alpha2M levels (Akuffo, et al., 2008, Giometto, et al., 1988, Licastro, et
al., 1995).
The promoter SNP (rs226379) analyzed in the present study is located near a previously
described positive-transcription regulatory element that differentially regulates the A2M
gene during replicative senescence (Li, et al., 2011). The findings from this previous study
suggest that A2M regional regulatory elements may be involved in the regulation of
alpha2M expression in a temporal or spatial manner (Li, et al., 2011). Both of the A2M
SNPs analyzed in the present study are located within transcription factor ChIP sequence
sites described by ENCODE, which further suggests that these SNPs may influence A2M
gene expression (Rosenbloom, et al., 2010).
The A2M gene lies in an AD linkage region on chromosome 12 (12p13.31) (Blacker, et al.,
1998, Liao, et al., 1998). Within this A2M region, other studies have investigated two
polymorphisms (rs3832852 and rs669) defined by a 5-bp insertion/deletion at a splice site of
exon 18 (Matthijs and Marynen, 1991). A2M polymorphisms rs3832852 and rs669 show
contrasting results in different AD populations (Blacker, et al., 1998, Liao, et al., 1998,
Panza, et al., 2006, Saunders, et al., 2003). The SNP rs669 has been associated with
argyrophilic grain disease (Ghebremedhin, et al., 2002), a disease that may have
neurofibrillary lesions that are typical of AD (Thal, et al., 2005), but meta-analyses of
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rs3832852 and rs669 association studies show no significant allele frequency differences
between AD cases and controls (Corder, et al., 1993), even after stratification by APOE ε4
(Koster, et al., 2000, Panza, et al., 2006). Most genetic studies of A2M genotypes, including
those evaluating an A2M haplotype, suggest a weak association with AD (Edwards, et al.,
2009, Flachsbart, et al., 2010). Haplotype analyses of A2M polymorphisms in APOE ε4 non-
carriers (Verpillat, et al., 2000) support initial reports of an association with AD and lend
some support to the results described in the present study, where APOE ε4 non-carriers who
carry the A2M rare allele have high CSF Aβ42 levels.
Previous reports suggest that the level of alpha2M expression is critical in amyloid
deposition (Cucullo, et al., 2003, Ozawa, et al., 2011), whereas the evidence we present here
suggests that A2M locus 5′ and 3′ genetic variation is associated with the modulation of CSF
Aβ42 levels in controls but not in AD patients. If SNPs within the regulatory regions of the
A2M gene influence A2M expression, a corresponding increase in alpha2M may lead to
efficient clearance of Aβ and thus to higher CSF Aβ42 levels. Furthermore, cognitively
normal controls with an A2M rs226379 A allele or an rs1805667 T allele may clear Aβ more
efficiently and may therefore have higher CSF Aβ42 levels than controls without these
alleles. In contrast, it has been reported that the modulation of Aβ clearance and deposition
leads to decreasing CSF Aβ42 levels in the early stages of cognitive decline and,
subsequently, to very low CSF Aβ42 levels in AD (Fagan, et al., 2006, Tapiola, et al., 2009,
Visser, et al., 2009). In our study, and in reports by others, it appears that low CSF Aβ42
levels in AD may contribute to a lack of a significant association between genotype (i.e.,
A2M or APOE) and CSF Aβ42 levels (Peskind, et al., 2006, Pirttila, et al., 1996).
In conclusion, to our knowledge, the present study is the first to identify an association
between CSF Aβ42 levels and SNPs in the A2M gene. Cognitively normal APOE ε4 non-
carriers with the A2M rare allele were found to have the highest CSF Aβ42 levels. Given that
low CSF Aβ42 levels are associated with increased Aβ deposition in the brain, these results
suggest that genetic variation within the A2M gene influences CSF Aβ42 levels and that A2M
rare allele carriers may be protected against Aβ deposition.
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Figure 1.
Cerebrospinal fluid (CSF) Aβ42 levels in cognitively normal control subjects and
Alzheimer’s disease (AD) patients.
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Figure 2.
Cerebrospinal fluid (CSF) Aβ42 levels in cognitively normal control subjects and
Alzheimer’s disease (AD) patients by APOE ε4 status. Differences between APOE groups
were tested with and without adjusting for gender, race, and age. Adjusted p values are in
parentheses.
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Figure 3.
Beta coefficients for cerebrospinal fluid (CSF) Aβ42 levels in cognitively normal control
subjects and Alzheimer’s disease (AD) patients per collapsed genotype. See the Statistical
analysis section for an explanation of how SNP effects were modeled. A confidence interval
which does not cross the vertical line at zero indicates that the difference in genotypes is
significant (p value < 0.05) before adjusting for multiple comparisons. A beta coefficient
(solid square for AD, circle for controls) to the right of the vertical line represents higher
CSF Aβ42 levels for the collapsed genotype group that contains minor alleles (EE or EF). #
Single-nucleotide polymorphism (SNP) effect of A2M SNP rs226379 in controls: p = 0.003;
Holm correction for multiple comparisons p = 0.06. * SNP effect of A2M SNP rs1805667 in
controls: p = 0.002; Holm correction for multiple comparisons p = 0.04.
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Figure 4.
Cerebrospinal fluid (CSF) Aβ42 levels in cognitively normal control subjects and
Alzheimer’s disease (AD) patients stratified by APOE ε4 and A2M single-nucleotide
polymorphisms (SNPs). A2M SNPs: rs226379 (EE, EF vs. FF: AA, AG vs. GG) (Panel A)
and rs1805667 (EE, EF vs. FF: TT, TG vs. GG) (Panel B). Differences between SNP groups
were tested separately for control participants and AD patients and were tested with and
without adjusting for gender, race, age, and APOE ε4 status. Adjusted p values are in
parentheses. P values do not take into account multiple comparisons.
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Figure 5.
Random forest variable importance plot for predicting cerebrospinal fluid (CSF) Aβ42
levels, using disease status, gender, race, age, APOE ε4 status, and the 24 single-nucleotide
polymorphisms (SNPs) (collapsed genotypes). Percent variance explained = 40%.
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Table 1
Sample Description
Controls (n = 168) AD (n = 99) P valuea
Age 67 (9; 52–88) 71 (10; 52–87) < 0.001
Female 103 (61%) 45 (45%) 0.02
Caucasian 153 (91%) 96 (97%) 0.11
APOE ε4+ 63 (38%) 65 (66%) < 0.0001
Age at onset 66 (9; 46–82)
Aβ42 (pg/ml) 152 (37; 73–240) 106 (28; 65–18f8) < 0.0001
Mean, standard deviation, and range shown for continuous variables; sample size and percent shown for categorical variables.
AD, Alzheimer’s disease; APOE ε4+, at least one APOE ε4 allele
a
P value based on the two-sample t-test for continuous variables and the chi-square test for categorical variables.
Neurobiol Aging. Author manuscript; available in PMC 2015 February 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Millard et al. Page 20
Ta
bl
e 
2
G
en
ot
yp
e 
Fr
eq
ue
nc
y 
D
ist
rib
ut
io
n
A
β D
eg
ra
da
tio
n 
G
en
es
G
en
e N
am
e
G
en
e L
oc
at
io
n
SN
P
SN
P 
Lo
ca
tio
n
Fr
eq
ue
nc
y
P-
va
lu
es
A
D
C
on
tr
ol
s
G
en
ot
yp
e
C
ol
la
ps
ed
 G
en
ot
yp
e
EE
EF
FF
EE
EF
FF
U
na
dj.
A
dj.
U
na
dj.
A
dj.
NE
P
N
ep
ril
ys
in
3q
25
.1
-q
25
.2
rs
98
96
92
5′ 
R
eg
io
n
0.
21
0.
43
0.
35
0.
18
0.
48
0.
34
0.
70
1
0.
51
1
0.
81
3
0.
74
3
rs
12
76
5
3′ 
R
eg
io
n
0.
06
0.
47
0.
46
0.
10
0.
31
0.
60
0.
02
4
0.
16
4
0.
03
8
0.
02
0
EC
E
En
do
th
el
in
-C
on
ve
rti
ng
 E
nz
ym
e
1p
36
.1
rs
21
30
45
5′ 
R
eg
io
n
0.
11
0.
46
0.
42
0.
11
0.
36
0.
52
0.
23
8
0.
29
7
0.
11
6
0.
15
4
rs
20
38
09
0
3′ 
R
eg
io
n
0.
09
0.
38
0.
53
0.
08
0.
36
0.
55
0.
90
2
0.
49
8
0.
65
4
0.
51
9
AC
E
A
ng
io
te
ns
in
 I 
co
nv
er
tin
g
en
zy
m
e
17
q2
3.
3
rs
42
93
In
tro
n 
2
0.
23
0.
44
0.
32
0.
17
0.
50
0.
33
0.
46
2
0.
65
7
0.
94
4
0.
91
1
rs
49
68
59
1
3′ 
R
eg
io
n
0.
16
0.
41
0.
42
0.
12
0.
51
0.
38
0.
31
1
0.
46
1
0.
42
6
0.
30
5
ID
E
In
su
lin
-d
eg
ra
di
ng
 e
nz
ym
e
10
q2
3-
q2
5
rs
24
21
94
5
In
tro
n 
1
0.
14
0.
49
0.
36
0.
12
0.
45
0.
42
0.
63
4
0.
72
8
0.
34
2
0.
46
8
rs
22
51
10
1
3′ 
R
eg
io
n
0.
06
0.
47
0.
46
0.
08
0.
40
0.
52
0.
52
0
0.
71
6
0.
40
1
0.
56
5
PL
G
Pl
as
m
in
og
en
6q
26
rs
21
44
72
3
5′ 
R
eg
io
n
0.
29
0.
48
0.
22
0.
19
0.
52
0.
29
0.
13
5
0.
00
6
0.
25
5
0.
11
5
rs
11
06
0
3′ 
R
eg
io
n
0.
23
0.
45
0.
31
0.
24
0.
40
0.
35
0.
71
6
0.
52
4
0.
52
5
0.
33
4
M
M
P9
M
at
rix
 m
et
al
lo
pe
pt
id
as
e 
9
20
q1
1.
2-
q1
3.
1
rs
39
18
25
3
In
tro
n 
3
0.
21
0.
52
0.
27
0.
27
0.
39
0.
33
0.
14
9
0.
70
1
0.
30
1
0.
25
0
rs
39
18
27
0
3′ 
R
eg
io
n
0.
01
0.
29
0.
70
0.
02
0.
24
0.
74
0.
61
8
0.
53
9
0.
46
8
0.
49
7
A
β C
le
ar
an
ce
 G
en
es
RA
G
E
R
ec
ep
to
r f
or
 a
dv
an
ce
d
gl
yc
at
io
n 
en
d 
pr
od
uc
ts
14
q3
2
rs
37
59
55
8
5′ 
R
eg
io
n
0.
01
0.
30
0.
69
0.
04
0.
33
0.
64
0.
38
4
0.
70
0
0.
40
7
0.
76
5
rs
71
52
62
7
3′ 
R
eg
io
n
0.
05
0.
36
0.
59
0.
04
0.
35
0.
61
0.
80
5
0.
52
2
0.
66
0
0.
58
0
LR
P1
Lo
w
 d
en
sit
y 
lip
op
ro
te
in
re
ce
pt
or
- r
el
at
ed
 p
ro
te
in
 1
12
q1
3-
q1
4
rs
47
59
27
5
In
tro
n 
1
0.
15
0.
48
0.
36
0.
13
0.
57
0.
30
0.
44
1
0.
58
8
0.
31
2
0.
25
4
rs
79
56
95
7
3′ 
R
eg
io
n
0.
11
0.
52
0.
37
0.
17
0.
44
0.
39
0.
34
7
0.
99
9
0.
75
7
0.
77
1
LR
P8
Lo
w
 d
en
sit
y 
lip
op
ro
te
in
re
ce
pt
or
- r
el
at
ed
 p
ro
te
in
 8
1p
34
rs
18
89
54
1
In
tro
n 
2
0.
09
0.
37
0.
54
0.
14
0.
40
0.
46
0.
39
8
0.
45
5
0.
26
2
0.
76
0
rs
51
77
3′ 
R
eg
io
n
0.
20
0.
43
0.
36
0.
19
0.
45
0.
36
0.
95
3
0.
85
3
0.
91
5
0.
98
4
AB
CB
1
A
TP
-b
in
di
ng
 c
as
se
tte
, s
ub
-
fa
m
ily
 B
 (P
-gl
yc
op
rot
ein
)
7q
21
.1
2
rs
13
23
33
08
In
tro
n 
1
0.
20
0.
46
0.
33
0.
29
0.
43
0.
29
0.
30
7
0.
07
7
0.
41
4
0.
25
1
rs
10
55
30
2
3′ 
R
eg
io
n
0.
02
0.
24
0.
74
0.
02
0.
31
0.
67
0.
50
2
0.
38
1
0.
26
6
0.
25
6
CL
U
Cl
us
te
rin
 (a
po
lip
op
rot
ein
 J)
8p
21
-p
12
rs
93
31
88
8
In
tro
n 
1
0.
12
0.
45
0.
42
0.
10
0.
40
0.
50
0.
48
5
0.
15
5
0.
23
1
0.
24
9
rs
30
87
55
4
3′ 
R
eg
io
n
0.
05
0.
26
0.
69
0.
05
0.
27
0.
68
0.
99
1
0.
58
8
0.
96
8
0.
68
9
A2
M
α2
-m
ac
ro
gl
ob
ul
in
12
p1
3.
31
rs
22
63
79
5′ 
R
eg
io
n
0.
10
0.
44
0.
45
0.
12
0.
44
0.
43
0.
83
2
0.
69
0
0.
75
0
0.
74
5
rs
18
05
66
7
3′ 
R
eg
io
n
0.
11
0.
42
0.
46
0.
13
0.
40
0.
46
0.
88
0
0.
88
2
0.
99
5
0.
94
2
U
na
dju
ste
d (
Un
ad
j.) 
an
d a
dju
ste
d (
Ad
j.) 
p 
v
al
ue
s a
re
 p
ro
vi
de
d.
 A
dju
ste
d p
 
v
al
ue
s a
re
 fo
r c
ov
ar
ia
te
s: 
ag
e,
 g
en
de
r, 
ra
ce
, a
nd
 A
PO
E 
ε4
 st
at
us
. P
 
v
al
ue
s a
re
 n
ot
 c
or
re
ct
ed
 fo
r m
ul
tip
le
 c
om
pa
ris
on
s.
Neurobiol Aging. Author manuscript; available in PMC 2015 February 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Millard et al. Page 21
A
D
, A
lz
he
im
er
’s
 d
ise
as
e;
 S
N
P,
 si
ng
le
-n
uc
le
ot
id
e 
po
ly
m
or
ph
ism
Neurobiol Aging. Author manuscript; available in PMC 2015 February 01.
